John A. Salon, et al. Serial No. 09/899,732 Filed: July 5, 2001

Page 2

فيه

.

Please delete the paragraph on page 1, lines 6-12.

In the Claims:

Please cancel claims 42 and 122-124 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

Please amend claim 198 as follows:

--198.

(Amended) A method of treating depression in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a MCH1 antagonist, wherein:

(a)

- (1) the MCH1 antagonist does not inhibit the activity of central monoamine oxidase A greater than 50 percent, at a concentration of 10mM; and (2) the MCH1 antagonist does not inhibit the activity of central monoamine oxidase B greater than 50 percent, at a concentration of 10mM; and
- (b) the MCH1 antagonist binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.--

Please add new claims 208-213 as follows:

62

.

--208. (New) A method of treating anxiety in a subject which comprises administering to the subject a composition

ć.

John A. Salon, et al. Serial No. 09/899,732 Filed: July 5, 2001

Page 3

comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a MCH1 antagonist, wherein the MCH1 antagonist binds to the MCH1 receptor with a binding affinity at least tenfold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.--

- --209. (New) The method of claim 208, wherein the MCH1 antagonist also binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the human 5HT_{1A}, human 5HT_{1B}, human 5HT_{1D}, human 5HT_{1E}, human 5HT_{2A}, rat 5HT_{2C}, human 5HT₄, human 5HT₆ and human 5HT₇ receptors.--
- --210. (New) The method of claim 208, wherein the MCH1 antagonist also binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human histamine $\rm H_1$ and $\rm H_2$ receptors.--
- --211. (New) The method of claim 208, wherein the MCH1 antagonist also binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human dopamine D_1 , D_2 , D_3 , D_4 and D_5 receptors.--
- --212. (New) The method of claim 208, wherein the MCH1 antagonist also binds to the MCH1 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human α_{1A}

BI

·.

16

.5

1